Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators propose that evidence of chronic cerebrospinal venous insufficiency (CCSVI) may be evident in the vasculature of the fundus. The investigators will be examining fundi of multiple sclerosis patients and Ehlers-Danlos patients to see if evidence of CCSVI can be found in these patients having high risk for CCSVI. The investigators will read the fundus photos, compared to age-matched normals in a "blind" fashion.
| Condition |
|---|
|
Ehlers-Danlos Syndrome Multiple Sclerosis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
| Official Title: | Vascular Fundus Changes in Patients With High Probability of CCSVI (Chronic Cerebrospinal Venous Insufficiency) |
- Fundus: venous engorgement/beading [ Time Frame: Baseline ] [ Designated as safety issue: No ]Abnormal vessel appearance in fundi may include venous engorgement and beading, abnormal A/V ratio, blurred disc margins, papilledema, dot hemorrhages or exudates.
| Estimated Enrollment: | 60 |
| Study Start Date: | May 2011 |
| Estimated Study Completion Date: | November 2012 |
| Primary Completion Date: | July 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Multiple sclerosis and or Ehlers-Danlos
Patients with suspected or confirmed cases of Ehlers Danlos Syndrome and or Multiple Sclerosis
|
|
Age matched normals
Age matched normals
|
Detailed Description:
Chronic Cerebrospinal Venous Insufficiency (CCSVI) has been proposed as the cause of numerous neurodegenerative diseases of the brain. CCSVI is the result of poor drainage of blood (and cerebral spinal fluid to some degree) from weakened or stenosed veins usually located in the cervical area (most notably the internal jugular veins). Although current focus and treatment of CCSVI is on multiple sclerosis, CCSVI has also been implicated as a potential cause of Alzheimer's disease and Parkinson's Disease. Additionally, patients with Ehlers-Danlos Syndrome (EDS) -- a disorder of connective tissue -- are more prone to developing multiple sclerosis than the general population. Many EDS patients are known to have weakened and abnormal blood vessels and 40 - 70% of EDS patients develop autonomic dysfunction in addition to numerous other symptoms found in patients with CCSVI. In the small subset of EDS and multiple sclerosis patients seen at Total Eye Care, the investigators have noticed a vascular irregularity (using the optomap® and examining the results under high magnification) which offers credence to the theory of CCSVI. Such objective data has been elusive, excepting for fMRI, ultrasound (to a limited degree) and venous angioplasty results. Current treatment of CCSVI involves the ballooning and sometimes stenting, of abnormally stenosed veins. The treatment of CCSVI offers hope to many patients suffering from multiple sclerosis. Although CCSVI research is in its infancy, many doctors believe that CCSVI is a significant portion of the solution to patients with neurodegenerative diseases of the brain. Because CCSVI is a vascular disorder, the investigators hypothesize that the investigators are able to screen candidates for CCSVI via the optomap®.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Aged-matched normals are patients at Total Eye Care. Multiple sclerosis and/or Ehlers-Danlos patients will be accepted from any area, and will not be excluded based on location of residence. They need not be patients of Total Eye Care.
Inclusion Criteria:
- age matched normals
- patients with diagnosed or suspected Ehlers-Danlos Syndrome and/or diagnosed or suspected Multiple Sclerosis ("CIS")
Exclusion Criteria:
- diabetics and patients unable to sit in position for testing are excluded
Contacts and Locations| United States, Texas | |
| Total Eye Care | |
| Colleyville, Texas, United States, 76034 | |
| Study Director: | Diana L Driscoll, O.D. | Genetic Disease Investigators |
| Principal Investigator: | Richard A Driscoll, O.D. | Genetic Disease Investigators |
| Study Chair: | Clair A Francomano, M.D. | Harvey Institute for Human Genetics |
More Information
Additional Information:
Publications:
| Responsible Party: | Diana Driscoll, O.D., Principal Investigator, Genetic Disease Investigators |
| ClinicalTrials.gov Identifier: | NCT01356134 History of Changes |
| Other Study ID Numbers: | 61/3527 |
| Study First Received: | May 12, 2011 |
| Last Updated: | July 14, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Genetic Disease Investigators:
|
multiple sclerosis ehlers danlos syndrome CCSVI |
chronic cerebrospinal venous insufficiency fundus retina |
Additional relevant MeSH terms:
|
Ehlers-Danlos Syndrome Multiple Sclerosis Sclerosis Venous Insufficiency Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Hemorrhagic Disorders Hematologic Diseases Skin Abnormalities Congenital Abnormalities Skin Diseases, Genetic |
Genetic Diseases, Inborn Collagen Diseases Connective Tissue Diseases Skin Diseases Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013